

Rhythm Adds Sonic Clinical Services To ColoSTAT[®] Clinical Trial

- **Sonic Clinical Services, a division of Sonic Healthcare (ASX: SHL) joins the ColoSTAT[®] Clinical Trial; and**
- **Sonic bring a network of independent clinicians across NSW and Victoria, with first patients having already been recruited.**

16 June 2021, Melbourne: Rhythm Biosciences (ASX: RHY) is pleased to confirm that the latest group to join Rhythm's ColoSTAT[®] clinical trial is Sonic Clinical Services' Independent Practitioner Network (IPN) Medical Centres.

IPN Medical Centres form part of the primary care division of Sonic Healthcare (ASX: SHL), and boast Australia's largest network of medical centres, with more than 2,000 doctors across 160 medical centres nationally. IPN provides more than 10 million patient consultations every year.

Rhythm CEO, Glenn Gilbert, commented:

"We are already working with Sonic Healthcare under an existing partnership for the storage and testing of ColoSTAT[®] blood samples as part of the Study 7 clinical trial. Expanding this partnership with an additional division, in Sonic Clinical Services' IPN, is a natural progression that will ultimately contribute to the success of the ColoSTAT[®] clinical trial."

With authority by the Board.

For further information, please contact:

Glenn Gilbert
Chief Executive Officer
+61 3 8256 2880

About Rhythm Biosciences

Rhythm Biosciences (ASX: RHY) is a transformative, predictive diagnostics company, specialising in early cancer detection. Rhythm's initial business pursuit is centred upon technology originally developed by the CSIRO and involves the development and commercialisation of a screening and diagnostic test for the early detection of colorectal cancer, the third biggest cause of cancer-related deaths globally.

Rhythm's lead product, ColoSTAT[®], is intended to be a simple, affordable, minimally invasive and effective blood test for the early detection of bowel cancer for the global mass market. It is expected to be comparable to, if not better than, the current standard of care, the faecal immunochemical test (FIT), at a lower cost. ColoSTAT[®] also provides an alternative for those who choose not to, or are unable to, be assessed using standard screening programs.

ColoSTAT[®] is designed to be used easily by laboratories without the need for additional operator training or additional infrastructure. ColoSTAT[®] has the potential to play an important role in reducing the morbidity and mortality rates and healthcare costs associated with colorectal cancer via increasing current screening rates.

Globally, over 850,000 people die from colorectal cancer each year. Colorectal cancer is typically diagnosed at a later stage when there is a poor prognosis for long-term survival. Annual estimated unscreened 50-74-year old's is estimated at +130m for the US, EU and AU alone, with this market potential being more than \$6.5b.